Participate in Alzheimer’s Disease Clinical Trial Today

Upcoming trials

The Trailrunner-ALZ 3 Study is a Phase 3 study using Remternetug for those with Early Alzheimer’s Disease. Approximately 1200 participants are expected to take part of the study.
For more information, please visit clinicaltrials .gov.
If you are interested in participating, please contact Claire CAeschimann@gengepartners.com
The Target Tau-1 Study is a Phase 3 study using an Anti-MTBR Tau Monoclonal Antibody for those with Early Alzheimer’s Disease. Approximately 475 participants are expected to take part of the study.
For more information, please visit clinicaltrials .gov.
If you are interested in participating, please contact Claire CAeschimann@gengepartners.com

If you would like to hear about more about our current or upcoming neurological clinical trials in Montreal please contact us at: info@gengepartners.com

“If we’re not in the beginning for rare disease, we may simply be too late for our patients to get the benefit of these new therapies.”

-Angela Genge

Our mission

To improve patient health and well-being by conducting cutting-edge clinical research. We strive to foster a culture of innovation, collaboration, and excellence in all aspects of our research, and to contribute to the global effort to improve healthcare for all.
Our vision

To be a leading force in advancing medical knowledge and improving patient care through innovative and ethical clinical research
Our future

Genge Partners will continue to be at the forefront of clinical research, utilizing the latest technologies and methodologies to bring new treatments and therapies to patients in need. Our commitment to patient safety, scientific rigor, and ethical conduct will remain steadfast, as we work to improve healthcare for all and make a lasting impact on the field of medicine.